# Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer - Triple Negative Breast Cancer

> **NCT01815242** · PHASE2 · COMPLETED · sponsor: **West German Study Group** · enrollment: 336 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** nab-Paclitaxel
- **DRUG:** Gemcitabine
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT01815242
- **Lead sponsor:** West German Study Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06
- **Primary completion:** 2015-03
- **Final completion:** 2025-01-15
- **Target enrollment:** 336 (ESTIMATED)
- **Last updated:** 2025-02-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01815242

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01815242, "Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer - Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT01815242. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*